Journal
NANOSCALE
Volume 10, Issue 36, Pages 16962-16983Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c8nr04073g
Keywords
-
Categories
Funding
- Crohn's & Colitis Foundation of America (CCFA) Career Award [348137]
- PhRMA Foundation Research Starter Award [RSGTMT17]
- McGee-Wagner Interdisciplinary Research Foundation
Ask authors/readers for more resources
Neurodegenerative diseases refer to disorders of the central nervous system (CNS) that are caused by neuronal degradations, dysfunctions, or death. Alzheimer's disease, Parkinson's disease, and Huntington's disease (APHD) are regarded as the three major neurodegenerative diseases. There is a vast body of literature on the causes and treatments of these neurodegenerative diseases. However, the main obstacle in developing an effective treatment strategy is the permeability of the treatment components at the bloodbrain barrier (BBB). Several strategies have been developed to improve this obstruction. For example, nanomaterials facilitate drug delivery to the BBB due to their size. They have been used widely in nanomedicine and as nanoprobes for diagnosis purposes among others in neuroscience. Nanomaterials in different forms, such as nanoparticles, nanoemulsions, solid lipid nanoparticles (SLN), and liposomes, have been used to treat neurodegenerative diseases. This review will cover the basic concepts and applications of nanomaterials in the therapy of APHD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available